Research

No Applicants // Limit: 3* // Tickets Available: 3

*The University of Arizona Cancer Center (UACC) can nominate up to three applicants (one per category) for the Susan G. Komen’s Brinker Awards for Scientific Distinction 2025 which recognizes pioneering work in breast cancer research and treatment. 

For more information please contact: UACC-PreAward.

Award Categories (Limit 1 Each) 

• The Brinker Award for Scientific Distinction in Basic Science will be presented to a basic science and/or translational researcher whose scientific discoveries or novel technologies have substantively impacted our understanding of the basic biology and intrinsic molecular processes driving breast cancer to improve breast cancer care.
• The Brinker Award for Scientific Distinction in Clinical Research will be presented to a clinical researcher who has advanced new approaches for prevention, detection, diagnosis and treatment that have paved the way for new clinical and therapeutic applications and/or practice changing, patient-focused care for breast cancer.
• The Brinker Award for Scientific Distinction in Population Science will be presented to a researcher who has made pivotal advances in implementing science, cancer care delivery, health services research, epidemiology and/or developed innovative evidence-based interventions to enhance breast cancer outcomes.

Limit: 2* // Tickets Available: 1

K. Huntoon (Neurosurgery)- V Scholar

The University of Arizona Cancer Center (UACC) can nominate can nominate up to two proposals: one Translational OR V Scholar nominee and one All-Star nominee (if eligible) for the V Foundation Pediatric Cancer Research Grant 2025.

For more information please contact: UACC-PreAward.

Eligibility

Nominee must meet all of the following criteria by the nomination due date:

• Nominated by their Cancer Center Director or similar high ranking research official.
• Employed at a non-profit research institution (e.g., 501c3, Section 170).
• Either a US Citizen or a permanent legal resident in the US
• See additional criteria for each mechanism listed in corresponding RFA within the Supporting Documents section above.

Limit: 1 // Tickets Available: 0

J. Streicher (Pharmacology)

Objective
The program's objective is to support projects that may be too innovative and speculative for traditional funding sources but still have a high likelihood of producing important findings. It is expected that investigations supported by these grants will yield high-impact findings and result in major grant applications and funding as well as significant publications in high-impact journals.

Eligibility
The nominated candidate must be a full-time associate professor or full professor at a US academic institution working in the area of studies of brain function in health and disease. Current major NIH or other peer-reviewed funding is preferred but evidence of such funding in the past three years is essential. Studies should be related to either normal human brain development or specifically identified disease states. This includes molecular and clinical neuroscience as well as studies of neural, sensory, motor, cognitive, behavioral and emotional functioning in health and disease. The grant proposal must detail a new research project that is not funded by other sources. This grant is not to be used as bridge funding. 

Investigators at institutions that are affiliated with a medical school or university are eligible to apply only through the institution where they hold a full-time faculty position. 

Scientists that have previously received a BRF Scientific Innovations Award may not receive the award for a second time until five years has elapsed since the beginning date of the prior award. Grant requirements from all previous awards must be met.  Only one PI may apply per application. (Applicant may include the name of a Co-PI within or from another institution, but no additional supporting materials for the Co-PI are required, including biosketch, current grants, abstracts, etc.) 

Limit: 1 // Tickets Available: 0

M. Baro (Anthropology) 

Eligibility
In fairness to other organizations seeking support, we ask that organizations submit only one concept application per round of funding.

Description
The Conservation, Food and Health Foundation seeks to protect the environment, improve food production, and promote public health in Africa, Asia, the Caribbean, Latin America, and the Middle East. 

For all fields of interest, please see the funding opportunity webpage.



 

The University of Arizona is not eligible to apply to the 2026 Beckman Scholars Program due to an existing award. 

If you have any questions, please contact RDS.

Limit: 1 // Tickets Available: 1

Kenry (Pharmacology and Toxicology) 

The University of Arizona Cancer Center (UACC) can nominate one individual for the 2026 Pew-Stewart Scholars for Cancer Research program. For more information please contact: UACC-PreAward.

In line with The Stewart Trust’s mission to invest in innovative, cutting-edge cancer research that may accelerate and advance progress toward a cure for cancer, applications are invited from nominees conducting cancer research at NCI-designated cancer centers, or cancer-focused institutions. The Pew-Stewart Scholars Program for Cancer Research is distinct from the Pew Scholars Program, and it follows a different, but parallel set of guidelines and procedures for nominating an applicant whose research is related to cancer.

In early April 2025, a letter of invitation and application instructions will be sent to the leaders of the cancer research institutions selected to submit a nominee for the 2026 class. Centers are expected to complete a limited submission competition in order to identify and select one nominee. For guidance on this process, please contact Pew-Stewart@pewtrusts.org.

• Center administration should distribute this invitation and award eligibility details to all investigators via an email announcement or website posting.
• Interested applicants should submit pre-proposal material to an internal selection committee for consideration.
• To nominate a candidate, a member of the internal selection committee must complete an online survey from the Pew program office describing the selection process used by the institution and submit the name and contact information of the chosen applicant by May 14, 2025.
• Nominations of applicants to the program will not be considered after May 14, 2025.
• The Pew program office will email grant application portal login information and a detailed application guide directly to all nominated applicants by June 11, 2025. The online application website will open on June 11, 2025.
• For research administrators assisting an applicant, please send an email with your grant applicant cc’ed to Pew-Stewart@pewtrusts.org after June 11, 2025, to receive access to the portal. No requests will be accepted prior to this date.
• The application submission deadline is Aug. 27, 2025.
• Every application will be reviewed by the program's National Advisory Committee. The committee will make recommendations to the board of directors of The Pew Charitable Trusts in April 2026. Candidates will be notified in April if they have been recommended to the Stewart and Pew boards.
• A public announcement of the award will be made in June. Grant agreements will be issued to the grant hosting institution of each scholar in August of the award year.

No Applicants // Limit: 2 (1 Translational nominee, 1 All-Star Translational nominee) // Tickets Available: 2 

The University of Arizona Cancer Center (UACC) can nominate up to two proposals: one Translational nominee and one All-Star Translational nominee (if eligible) for the V Foundation Adult Translational Cancer Research Award 2025. 

For more information please contact: UACC-PreAward.

Purpose of Award:

The UACC is seeking nominations for the Translational Adult Cancer Research Grant which advances basic laboratory discoveries towards clinical use, ultimately improving human health and is restricted to adult cancer research.

This Translational grant is restricted to adult cancer research in the preclinical or translational space with a focus on bench-to-bedside strategies. Research on ANY adult cancer type can be funded. Applicants may propose cancer research that moves a novel strategy from the laboratory into a human clinical trial or uses specimens from a clinical trial to test hypotheses, develop biomarkers, or mechanisms. The research must apply in a direct way to human beings within 3 years from the end of the grant. If biomarker research is undertaken, a validation set or independent clinical trial is essential. A plan for biomarker validation, if applicable, must be included in any proposal. The endpoint of the project should be the planning or initiation of a new clinical trial or conducting an investigator-initiated trial with laboratory correlates that test hypotheses. Research areas not included in this scope are epidemiology, behavioral science, and health services research.

Limit: 1 per SIP

K. Ellingson (Public Health) for SIP25-005 Understanding the potential of early childcare and education (ECE) centers in promoting childhood vaccines and RSV prevention products

S. Carvajal (College of Public Health's Prevention Research Center) for SIP25-006 Overdose Prevention and Treatment Research Network (OPTRN)

Eligibility: 
Only one application per SIP per institution is allowed (e.g., multiple applications for the same SIP (listed in Section VIII) from the same institution are NOT permitted).

Purpose:
This Notice of Funding Opportunity (NOFO) invites applications from CDC Health Promotion and Disease Prevention Research Centers (PRCs), selected for funding under RFA-DP-24-004, to apply for supplemental funding to conduct Special Interest Research Projects (SIPs) to inform public health practice. PRCs will conduct high-quality applied health promotion and disease prevention research projects in real-world settings to identify, design, test, evaluate, disseminate, and translate interventions (i.e., programs, practices, policies, or strategies) to prevent and reduce risk for the leading causes of illness, disability, and death in the United States.

No Applicants // Limit: 2 // Tickets Available: 2

Number of Applications
The NIH will not accept duplicate or highly overlapping applications under review at the same time, per 2.3.7.4 Submission of Resubmission Application. This means that the NIH will not accept:

• A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
• A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
• An application that has substantial overlap with another application pending appeal of initial peer review (see 2.3.9.4 Similar, Essentially Identical, or Identical Applications).

Two applications per institution (with a Unique Entity Identifier ) and a unique NIH eRA Institutional Profile File (IPF) number) are allowed per review round. The same or a similar topic may be submitted for subsequent review rounds involving the same or a similar team, but must be presented as a New application, not a Resubmission.

Applications that are not considered to be within the NIGMS mission will not be reviewed. Eligibility and appropriateness to the NIGMS mission will be evaluated again after review and prior to funding. Applications outside the NIGMS mission will not be funded. Given that only two applications are permitted per institution per review round, it is important to contact NIGMS staff before committing to any particular team and its topic area.

Purpose: 
This Funding Opportunity Announcement (FOA) is designed to support highly integrated research teams of three to six Program Directors/Principal Investigators (PDs/PIs) to address ambitious and challenging research questions that are within the mission of NIGMS. Project goals should not be achievable with a collection of individual efforts or projects. Collaborative program teams are expected to accomplish goals that require considerable synergy and managed team interactions. Teams are encouraged to consider far-reaching objectives that will produce major advances in their fields.

This FOA is not intended for applications that are mainly focused on the creation, expansion, and/or maintenance of community resources, creation of new technologies, or infrastructure development.

Limit: 1 // Tickets Available: 0
Q. Hao (Aerospace & Mechanical Engineering) 

Eligibility 
One (1) per organization as lead institution.

The scientific focus of the MIP program is subject to change from competition to competition. Information about the existing MIPs, from two previous competitions in 2015 and 2019, can be found at mip.org. The third MIP competition, in 2025, will accept proposals on alloys, amorphous, and composite materials. Given that the second MIP competition included an emphasis on biomaterials and polymer research, proposals mainly on these topics will not be considered in the third MIP competition.